Participating Companies

Abide Tx
Serine hy­dro­lase-tar­get­ed ther­a­peu­tics har­ness­ing the en­do­cann­abi­noid sys­tem to ad­dress neu­ro­log­i­cal and pain di­s­or­ders w. limit­ed or no treat­ment op­tions. Ph 2: Tourette Syn­drome on­go­ing with da­ta... [more in­for­ma­tion]
Affimed N.V. [AFMD] US$250 MM MCap
Mo­d­u­lar ROCK™plat­form en­abling mul­ti-spe­cif­ic NK / T-cell bi-and tri-spe­cif­ic Abs. Aug 2018 deal with Ge­nen­tech ($96M up­front / $5B po­ten­tial) to de­vel­op NK-cell en­gager-based ther­a­peu­tics through... [more in­for­ma­tion]
Anterra Capital
An­ter­ra is the lead­ing biotech in­ves­tor in the plant and an­i­mal sci­ence in­dus­tries. From the dis­cov­ery of nov­el her­bi­cides to the gene en­gi­neer­ing of dis­ease re­sis­tant an­i­mals, An­ter­ra is lev­er­ag­ing... [more in­for­ma­tion]
AxoGen [AXGN] US$795 MM MCap
Rev gen­er­at­ing; ad­dress­ing pe­ripher­al nerve re­pair w port­fo­lio of re­gen­er­a­tive medicine prod­ucts in US, Ca­na­da et al. Prod­ucts in­cl. Avance Nerve Graft: off-the-shelf com­mer­cial­ly avail pro­cessed... [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] US$2,251 MM MCap
De­vel­op­ing a port­fo­lio of in­no­va­tive, late-stage prod­uct can­di­dates tar­get­ing neu­ro­log­i­cal dis­eas­es, in­clud­ing rare di­s­or­ders. Lead de­vel­op­ment pro­grams in­clude mul­ti­ple com­pounds across its CGRP... [more in­for­ma­tion]
Carisma Therapeutics Inc.
Pi­oneer­ing the de­vel­op­ment of CAR macrophages, a dis­rup­tive ap­proach to im­munother­a­py. The tech­nol­o­gy lev­er­ages ad­vances in macrophage bi­ol­o­gy, chimer­ic anti­gen re­cep­tor en­gi­neer­ing and adop­tive... [more in­for­ma­tion]
Cellectis SA [CLLS] US$739 MM MCap
Lead­er in en­gi­neered al­lo­gene­ic (off-the-shelf) CAR-T ther­a­peu­tics. Pipe­line in­cludes pro­pri­e­tary pro­grams and Pfiz­er and Servi­er part­n­er­ships on nu­mer­ous tar­gets in on­col­o­gy. Lead in­ter­nal pro­gram... [more in­for­ma­tion]
CTI BioPharma [CTIC] US$56 MM MCap
Lead can­di­date pa­cri­tinib, oral ki­nase in­hibi­tor w spe­ci­fic­i­ty for JAK2, FLT3, IRAK1, and CS­F1R in Ph 2 for treat­ment of myelo­fi­bro­sis. Up­com­ing ca­t­alysts: pa­cri­tinib PAC203 Ph 2 da­ta - mid'19,... [more in­for­ma­tion]
CureVac AG
Found­ing Co of mR­NA space (last round $1bn+). Na­t­u­ral­ly se­quenced, op­ti­mized mR­NA. In­tra­tu­mo­ral ther­a­py Ph1 (mul­ti­ple onc in­di­ca­tions) ini­ti­at­ed Q4 17, ear­ly da­ta rep at SITC. First pt en­rolled Ph 1... [more in­for­ma­tion]
EOC Pharma
EOC is a Shang­hai-based bio­phar­ma­ceu­ti­cal com­pany that is fo­cused on the in-li­cens­ing of in­no­va­tive glob­al on­col­o­gy prod­ucts, and de­vel­op­ing, man­u­fac­tur­ing and com­mer­cial­iz­ing them for the Chi­na... [more in­for­ma­tion]
Evofem Biosciences, Inc. [EVFM] US$100 MM MCap
Am­pho­ra: Mul­ti­pur­pose Vag­i­nal pH Reg­u­la­tor (MVP-R) be­ing de­vel­oped as a non-hor­mo­n­al, on-de­mand, wo­m­an-con­trolled con­tra­cep­tive vag­i­nal gel; cur­rent­ly com­plet­ing con­fir­ma­to­ry Ph 3 in 1400 wo­m­en in US. [more in­for­ma­tion]
Hutchison China MediTech Ltd ("Chi-Med") [HCM] US$3,810 MM MCap
Chi-Med's pipe­line has eight nov­el late stage on­col­o­gy can­di­dates with six Phase 3 trials and 20+ Phase 1b/2 trials cur­rent­ly un­der­way that are fu­eled by its pro­f­itable Chi­nese com­mer­cial plat­form. [more in­for­ma­tion]
I-Mab Biopharma
I-Mab Bio­phar­ma is a Chi­na based bio­phar­ma­ceu­ti­cal with fo­cus on de­vel­op­ing in­no­va­tive bi­o­log­ics in the ar­eas of im­muno-on­col­o­gy and au­toim­mune dis­ease for the glob­al mar­kets, in­clud­ing Chi­na; The... [more in­for­ma­tion]
Kadmon Holdings, Inc. [KDMN] US$352 MM MCap
Late-stage biotech de­vel­op­ing small molecules and bi­o­log­ics; fo­cused on in­flam­ma­tion, fi­bro­sis and I-O. Lead can­di­date KD025 is a ROCK2 in­hibi­tor in a reg­is­tra­tion trial cGVHD. Plat­form of ROCK... [more in­for­ma­tion]
Mabspace Biosciences
MabS­pace Bio­s­ciences fo­cus­es on the dis­cov­ery and de­vel­op­ment of anti­body-based ther­a­peu­tics for can­cer and fi­brot­ic dis­eas­es. MabS­pace uti­l­izes its pro­pri­e­tary plat­form tech­nol­o­gy, im­mune tol­er­ance... [more in­for­ma­tion]
Medigene AG [MDG1:DB] €214 MM MCap
Lead­er in T Cell im­munol­o­gy. TCR tar­get­ing PRAME (AML, MDS, MM) en­tered clin­ic March 2018. CTA sub­mitt­ed for TCR tar­get­ing MAGE-A1 (MM, liv­er, and lung can­cer); sev­er­al add'l undis­closed tar­gets &... [more in­for­ma­tion]
Medivir AB [MVIR.B-SE]
Late stage broad pipe­line: remeti­no­s­tat, Ph 3 ready top­i­cal HDAC in­hibi­tor for ear­ly-stage cu­ta­neous T-cell lym­pho­ma; MIV-711, cathepsin K in­hibi­tor for OA, Ph 2 da­ta showed dis­ease mod­i­fy­ing ef­fect... [more in­for­ma­tion]
Minerva Neurosciences, Inc. [NERV] US$296 MM MCap
Ph 3 trial w/rolu­peri­done tar­get­ing neg­a­tive symp­toms as­soc w/ schi­zophre­nia; du­al MOA (5-HT2A & Sig­ma2 an­ta­g­on­ist); top-line da­ta 1H19. 3 Ph 2b trials on­go­ing w/ sel­torex­ant, in­clud­ing two in MDD and... [more in­for­ma­tion]
Motif Bio plc [MTFB] US$33 MM MCap
PD­U­FA date: Feb 13, 2019 for Antibi­ot­ic Iclaprim. Two Phase 3 trials in pts w acute bac­te­rial skin and skin struc­ture in­fec­tions (ABSS­SI) achieved pri­mary and se­condary end­points. Com­pared to SoC... [more in­for­ma­tion]
Nanobiotix SA [NANO:PA] €229 MM MCap
Nano­par­ti­cle-based ra­dio-en­hancer NBTXR3 for soft tis­sue sar­co­ma, head and neck, liv­er, pros­tate, rec­tal and other can­cers. Al­so de­vel­oped for in si­tu vax in comb w I/O ap­proach­es. NanoXray tech­nol­o­gy... [more in­for­ma­tion]
De­vel­op­ing first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. Lead can­di­date, NRX-101 in Ph 2b/3 de­vt (Break­thru Desig­na­tion, SPA and Fast Track Desig­na­tion by FDA) for... [more in­for­ma­tion]
NexImmune, Inc.
Pri­vate IO com­pany de­vel­op­ing unique ap­proach to anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing... [more in­for­ma­tion]
Oncopeptides AB [ONCO:ST] SKr7,082 MM MCap
De­vel­op­ing Melflufen (Yga­lo): alky­lat­ing pep­tide in class of Pep­ti­dase En­hanced Com­pounds tar­get­ing MM trans­for­ma­tion pro­cess, se­lec­tive­ly tar­gets MM. MoA over­comes re­sis­tance mech­anisms for cur­rent... [more in­for­ma­tion]
Oryzon Genomics [ORY:MA]
De­vel­op­ing treat­ments for the un­der­ly­ing caus­es of can­cer and CNS dis­eas­es by tar­get­ing ly­sine spe­cif­ic demethy­lase 1 (LS­D1, aka KD­M1A), an epi­ge­net­ic hi­s­tone mod­i­fy­ing en­zyme. Lead CNS com­pound... [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €500 MM MCap
RU­CON­EST (rhC1INH) mar­ket­ed to treat acute Hered­i­tary An­gioede­ma (HAE) at­tacks with 100% re­sponse rate, no re­lapse, side ef­fects, or plas­ma risk. On­ly prod­uct with fu­ture po­ten­tial to be ap­proved for... [more in­for­ma­tion]
PhaseBio Pharmaceuticals, Inc. [PHAS] US$165 MM MCap
De­vel­op­ing ther­a­pies for treat­ment of or­phan dis­eas­es; ini­tial fo­cus on car­diopul­mo­nary di­s­or­ders. Lead can­di­date PB2452, in Ph 1 as a re­v­er­sal agent for an­ti­platelet ther­a­py tica­grelor. Al­so... [more in­for­ma­tion]
Phosphagenics [PPGNY] US$1 MM MCap
Sol­u­bil­i­sa­tion / drug de­liv­ery tech­nol­o­gy TPM (Tar­get­ed Pen­e­tra­tion Ma­trix) com­bines mul­ti­ple forms of Vi­ta­min E. Plat­form en­hances us­a­bil­i­ty char­ac­teris­tics for in­jecta­bles, patch and gel prod­ucts. [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$153 MM MCap
Plat­form tech­nol­o­gy com­pany de­vel­op­ing An­ti­calins (en­gi­neered lipo­calin pro­teins) for on­col­o­gy and re­s­pi­ra­to­ry dis­eas­es. 2H18 Phase 1 da­ta for: 1) ful­ly-pro­pri­e­tary IO pro­gram PRS-343 for HER2+ solid... [more in­for­ma­tion]
Poxel SA [POXEL:PA] €193 MM MCap
Safe/more ef­fec­tive ther­a­pies for metabolic dis­eas­es. Imeglimin (mi­to­chon­dria-based MOA) for T2D be­gan Ph 3 in Ja­pan with Asian part­n­er Su­m­i­t­o­mo Dainip­pon. Com­ple­tion of Phase 3 on track for 2019 and... [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] US$321 MM MCap
Pro­pri­e­tary pep­tide tech­nol­o­gy plat­form to de­vel­op oral tar­get­ed ther­a­py-based drugs that work by block­ing bi­o­log­i­cal path­ways cur­rent­ly tar­get­ed by mar­ket­ed in­jectable anti­body drugs, and in­jecta­bles... [more in­for­ma­tion]
PsiOxus Therapeutics
IV ad­min­is­tered T-SIGn on­co virus plat­form trans­forms ade­n­ovirus in­to “armed” vec­tor. The ther­a­py (NG-348), us­es virus to tran­s­port two ther­a­peu­tic genes di­rect­ly in­to tu­mors to re­cruit im­mune... [more in­for­ma­tion]
Rumi Scientific
RU­MI Sci­en­tif­ic has de­vel­oped a trans­for­ma­tive pro­cess for screen­ing and test­ing ther­a­peu­tics against ge­net­ic dis­eas­es faster and more ef­fec­tive­ly than other avai­l­able tech­nolo­gies. Through the... [more in­for­ma­tion]
Savara Inc. [SVRA] US$278 MM MCap
Or­phan lung dis­ease co. Mol­gradex, Ph 3, in­haled GM-CSF: au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP), Ph 2a: non­tu­ber­cu­lous my­cobac­te­ria (NTM) lung in­fec­tion, and prep for Ph 2a in CF af­fect­ed... [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] US$279 MM MCap
Com­mer­cial stage Com­pany fo­cused on rare dis­eas­es with sig­ni­f­i­cant un­met needs. En­docrine franchise in­cludes RE­COR­LEV™, cor­ti­sol syn­th­e­sis in­hibi­tor in Ph 3 studies for en­doge­nous Cush­ing's... [more in­for­ma­tion]
Targovax [TRVX:OS] NKr540 MM MCap
En­gi­neered on­co­lyt­ic virus armed w im­mune-sti­m­u­lat­ing trans­genes for pa­tients w solid tu­mors. Ph 1 and Ph 1/2 trials on­go­ing with mul­ti­ple da­ta read­outs in 2018 and 2019. CMO de­vel­oped Yer­voy at BMS. [more in­for­ma­tion]
Vericel Corporation [VCEL] US$796 MM MCap
Ad­vanced cell ther­a­py; mar­ket­ing MA­CI (car­ti­lage re­pair) and Epi­cel (skin re­place­mentt) in TAMs of $2b+. Epi­cel mar­ket: $2b+. Re­cord 3Q18 rev­enues of $22.5 M rep­re­sents 58% YOY in­crease. FY gui­dance... [more in­for­ma­tion]
Veru Inc. [VERU] US$100 MM MCap
Ad­dress­ing pros­tate can­cer and spec phar­ma in urol­o­gy. Zu­clomiphene in Ph 2 treat­ing hot flash­es caused by hor­mone treat­ment for pros­tate can­cer. VERU-111: oral, next-gen, an­ti­tubu­lin agent for... [more in­for­ma­tion]